Abivax Shares Surge Amid Takeover Speculation

Abivax shares rose 6.9% in Paris amid takeover speculation. A Betaville alert circulated on Friday suggesting the company had attracted takeover interest. Abivax ADRs gained 6%. The company has yet to comment on the speculation.

Abivax (NASDAQ: ABVX) shares rose 6.9% in Paris on September 2, 2025, amid speculation of potential takeover interest. Traders cited a Betaville "uncooked" alert that circulated on Friday, suggesting the company has attracted interest from a large American pharmaceutical company [1]. The company's ADRs also gained 6% on the news.

This surge in share price comes after Abivax's lead asset, obefazimod, reached its primary goals in two Phase 3 trials for ulcerative colitis, an inflammatory bowel disorder. The positive results led to a 44-week maintenance trial, which was announced on July 23, 2025, and triggered a significant increase in the company's stock price [2].

The potential takeover speculation follows a pattern of increased interest in biotech companies with promising pipeline data. Traders and investors are closely monitoring the situation, as any acquisition could have a significant impact on the company's valuation and future prospects.

Abivax is scheduled to report its results on Monday, which may provide further clarity on the company's financial health and the potential for additional catalysts. The company's strong Phase 3 results have positioned it as a potential target for strategic acquirers seeking to expand their portfolios in the biotech sector.

References:
[1] https://www.ainvest.com/news/abivax-stock-surges-takeover-speculation-2509/
[2] https://seekingalpha.com/news/4492772-abivax-jumps-amid-takeover-speculation